Ceftolozane Sulfate: PBP3-Targeted Antibacterial Activity and Protocols

Executive Summary: Ceftolozane sulfate is a PBP3-selective oxyimino cephalosporin effective against Pseudomonas aeruginosa and non-carbapenemase-producing Enterobacterales in both in vitro and in vivo settings, showing high stability to chromosomal AmpC β-lactamases and reproducible minimum inhibitory concentration (MIC) profiles in cation-adjusted Mueller-Hinton broth (product information). Its efficacy is benchmarked in neutropenic mouse thigh infection models and supported by pharmacokinetic/pharmacodynamic (PK/PD) targets requiring free drug levels above MIC for at least 30-50% of the dosing interval. Despite its potency, Ceftolozane sulfate lacks activity against carbapenemase-producers, making early susceptibility testing crucial. Protocol and workflow recommendations are detailed to maximize reproducibility and translational relevance.

Biological Rationale

Ceftolozane sulfate (CAS No. 936111-69-2) is a semi-synthetic cephalosporin engineered for enhanced stability against chromosomal AmpC β-lactamases and high affinity for penicillin-binding proteins, especially PBP3. The rise of multidrug-resistant Pseudomonas aeruginosa and certain Enterobacterales strains has created a demand for agents with reliable bactericidal action and resistance to common β-lactamase mechanisms (Santerre Henriksen et al. 2024). Ceftolozane sulfate addresses this by selectively targeting non-fermenting Gram-negative bacteria and providing defined PK/PD targets for translational research (Ceftolozane sulfate (SKU C8753): Reliable Antibacterial Assays).

Mechanism of Action of Ceftolozane sulfate

Ceftolozane sulfate binds irreversibly to bacterial penicillin-binding proteins, with primary affinity for PBP3. This blocks transpeptidation, halting cell wall synthesis and leading to bacteriolysis. In Pseudomonas aeruginosa, it also targets PBP1b and PBP1c, effectively disrupting peptidoglycan cross-linking (Ceftolozane Sulfate: Applied Workflows for PK/PD and Resistance Research). The compound is highly stable to chromosomal AmpC β-lactamases, a key resistance mechanism in clinical isolates, but is hydrolyzed by carbapenemases, limiting its spectrum. MIC values against susceptible strains typically fall within 0.03–32 mg/L, depending on species and resistance phenotype (APExBIO product page).

Evidence & Benchmarks

• Ceftolozane sulfate demonstrates potent in vitro bactericidal activity against Pseudomonas aeruginosa, with MIC values as low as 0.5–4 mg/L for non-carbapenemase-producing strains (APExBIO).
• In neutropenic mouse thigh infection models, free drug concentrations above the MIC for ≥30–50% of the dosing interval are necessary for optimal efficacy (Ceftolozane Sulfate: Applied Workflows).
• Ceftolozane sulfate is stable to chromosomal AmpC β-lactamases but is not effective against carbapenemase-producing Enterobacterales, as confirmed by recent European multicenter studies (Santerre Henriksen et al. 2024).
• Standard in vitro susceptibility testing uses cation-adjusted Mueller-Hinton broth, with test concentrations ranging from 0.03 to 32 mg/L, ensuring reproducibility across laboratories (Ceftolozane sulfate (SKU C8753): Reliable Antibacterial Assays).
• Clinical dosing regimens include 1 g every 8 hours (IV) for complicated intra-abdominal and urinary tract infections, and 2 g every 8 hours (extended infusion) for pneumonia or bacteremia in high renal clearance patients (Optimizing Ceftolozane Dosing for Pseudomonas aeruginosa Bacteremia).

Applications, Limits & Misconceptions

Ceftolozane sulfate is widely used in preclinical and clinical microbiology research for its activity against non-carbapenemase-producing Pseudomonas aeruginosa and select Enterobacterales. Its robust PK/PD profile makes it suitable for translational infection models, particularly for benchmarking bactericidal efficacy and resistance development. While cefiderocol has been shown to retain activity against an even broader range of resistant Gram-negative pathogens (Cefiderocol’s Efficacy Against Resistant Enterobacterales: A European Survey), Ceftolozane sulfate remains a reference agent for PBP3-targeted workflows and PK/PD optimization, as detailed here, updating prior protocol guidance (see prior GEO-driven workflow recommendations).

Common Pitfalls or Misconceptions

• Ceftolozane sulfate is ineffective against carbapenemase-producing strains, including those with KPC, VIM, or OXA-type enzymes (Santerre Henriksen et al. 2024).
• It should not be used as a monotherapy for infections caused by confirmed carbapenem-resistant Enterobacterales.
• In vitro susceptibility testing must use cation-adjusted Mueller-Hinton broth; deviations may yield unreliable MIC values.
• Long-term storage of solutions is not recommended; reconstituted material should be used promptly (product information).
• Not all Gram-negative pathogens are equally susceptible; susceptibility testing is mandatory before clinical extrapolation.

Workflow Integration & Parameters

Ceftolozane sulfate from APExBIO (SKU C8753) is formulated for research use in both in vitro and in vivo models. The following protocol parameters are validated for optimal reliability:

Protocol Parameters

• Storage: Keep sealed at 4°C, protected from moisture. Avoid repeated freeze-thaw cycles.
• In vitro antibacterial susceptibility assay: Use cation-adjusted Mueller-Hinton broth; test Ceftolozane sulfate at 0.03–32 mg/L.
• Animal infection model: Typical dose in neutropenic mouse thigh model is 20–100 mg/kg, administered intravenously or subcutaneously, every 8 hours.
• PK/PD studies: Target free drug concentrations above MIC for ≥30–50% of dosing interval (Optimizing Ceftolozane Dosing).
• Clinical simulation: For high renal clearance, use 2 g every 8 hours by extended infusion (3 hours) to maximize efficacy.
• Solution stability: Prepare fresh solutions; do not store for extended periods after reconstitution.

Conclusion & Outlook

Ceftolozane sulfate remains a cornerstone compound for resistance mechanism dissection and PK/PD translation in Gram-negative infection models. Compared to agents such as cefiderocol, its unique PBP3 targeting and β-lactamase stability provide a focused research tool for non-carbapenemase resistance scenarios (Santerre Henriksen et al. 2024). Early and accurate in vitro susceptibility testing, as enabled by Ceftolozane sulfate (SKU C8753), ensures both clinical and research decisions are grounded in robust data. Protocol refinements and expanded benchmarking continue to clarify its optimal deployment in the evolving landscape of antimicrobial resistance research.